3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
13
Glioblastoma
10
Glioma
7
Astrocytoma
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Brain Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Seroma
1
Rectal Neoplasms
1
Pleural Neoplasms
1
Pleural Effusion, Malignant
1
Pleural Effusion
1
Pleural Diseases
1
Patient Preference
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Inflammatory Breast Neoplasms
1
Interventions
pembrolizumab
20
Cisplatin
17
Cetuximab
13
Docetaxel
11
Paclitaxel
9
Carboplatin
9
Radiotherapy
8
Fluorouracil
6
cemiplimab
5
130-nm albumin-bound paclitaxel
5
Bleomycin
4
Radiation
3
Pemetrexed
3
Panitumumab
3
Nivolumab
3
Gemcitabine
3
Albumin-Bound Paclitaxel
3
vandetanib
2
talimogene laherparepvec
2
selinexor
2
motexafin gadolinium
2
figitumumab
2
brigatinib
2
avelumab
2
atezolizumab
2
alpha-2'-deoxythioguanosine
2
advexin
2
Taxes
2
ON 01910
2
Methotrexate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Squamous Cell
×
Surgical Procedures, Operative
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled